Eli Lilly's Operating Margin Doubles Amid Volume Growth
In the second quarter ended June 2026, Eli Lilly (LLY) reported an operating margin of 49.7%, nearly double its historical average of 25.8%. This significant increase was driven by volume growth rather than price increases, with U.S. prices declining by 3% and up to 9% when excluding rebate adjustments. The company's blockbuster drugs Mounjaro and Zepbound contributed $14.9 billion in revenue for the quarter. Eli Lilly has raised its full-year 2026 revenue guidance to between $85 billion and $87 billion, with a non-GAAP performance margin range of 49% to 50.5%. The company's Medicare GLP-1 Bridge program expanded access for obesity treatments in July 2026 but is expected to lead to further U.S. price declines starting Q4 2026 as broader pharmacy coverage begins. The sustainability of Eli Lilly’s current margin expansion depends on continued volume growth outpacing net price erosion, with the company's shares up 78% over the past twelve months and trading near their 52-week high.
Tickers: $LLY